300+ mg of magnesium daily improved 10 cardiometabolic measures - meta-analysis

Comprehensive Effects of Magnesium Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose–Response Meta-Analysis

Nutrients (MDPI), 25 July 2026, https://doi.org/10.3390/nu18152435

Shooka Mohammadi, Andrea Palermo, Pantea Ojani, Navid Alaghemand, Pouyan Sanjari Pirayvatlou, Mohammadreza Mirkarimi, Sara Ayazian Mavi, Kia Tahouri, Shokoufeh Shokouhifar, Yeganeh Ettehad, Aida Borzabadi, Damoon Ashtary-Larky, Katsuhiko Suzuki, Cristina Bouzas, Daniela Rodrigues, Josep A. Tur

image

Summary by Claude - August, 2026

Magnesium supplements produce small but real improvements across many cardiometabolic measures — and no improvement at all in about half of the ones tested.

This systematic review pooled 78 randomized controlled trials with 5,226 adults, doses from 20 to 1,782 mg/day, durations 3 to 52 weeks. Four-fifths of the trials used ≥300 mg/day and two-thirds ran ≥12 weeks.

Improved: systolic BP −2.5 mmHg, diastolic BP −1.6 mmHg, fasting glucose −3.6 mg/dL, HbA1c −0.15%, HOMA-IR −0.48, triglycerides −9.2 mg/dL, LDL −3.2 mg/dL, HDL +1.5 mg/dL, IL-6 −1.1 pg/mL, body weight −0.7 kg.

Not improved: BMI, waist and hip circumference, body fat %, fasting insulin, total cholesterol, CRP, TNF-α, creatinine, ALT, AST.

Benefits for glucose, lipids, and blood pressure clustered in trials using ≥300 mg/day for ≥12 weeks, and in people who started off worse (higher fasting glucose, higher triglycerides, BP ≥130, HDL under 50). Safety looks reassuring: a prior review of 49 trials up to 972 mg/day found no serious adverse events, with loose stools the usual complaint — though people with chronic kidney disease need caution.

What this does not show / limitations. These are surrogate markers, not heart attacks or deaths. The authors are blunt: results show "favorable changes in intermediate cardiometabolic biomarkers rather than definitive evidence." GRADE certainty was very low for triglycerides and LDL, low for 8 more outcomes; heterogeneity ran as high as I²=97%. Publication bias was detected for LDL, body weight, and triglycerides. Only 3 trials lasted ≥25 weeks. Baseline magnesium status was reported so inconsistently that the key question — do deficient people benefit most? — could not be tested. Vitamin D was not measured in any analysis, so this says nothing directly about the D–Mg interaction.

PDF


Related in VitaminDWiki

Following do not appear to be mentioned in this study

Not mentioned in this study, but VitaminDWiki has many (10+) studies: